{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:16:00Z","timestamp":1791389760063,"version":"4.3.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00210-025-03978-3","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:31:42Z","timestamp":1741350702000},"page":"9609-9622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging therapeutic application of clemastine: a review of recent patents updates"],"prefix":"10.1007","volume":"398","author":[{"given":"Simran","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"3978_CR1","doi-asserted-by":"publisher","unstructured":"Abd-Rabou AA, Ahmed HH, Eskander EF (2017) Clemastine, the H1 histamine receptor antagonist, alters the human sex and thyroid hormonal profiles. Asian J Pharm Clin Res 10:327\u2013330. https:\/\/doi.org\/10.22159\/ajpcr.2017.v10i8.19456","DOI":"10.22159\/ajpcr.2017.v10i8.19456"},{"key":"3978_CR2","unstructured":"Adams D, Tesar PJ, Allimuthu D (2020) Compounds for treating myelin related disorders. WO2020072456A1. https:\/\/patents.google.com\/patent\/WO2020072456A1\/en?oq=WO2020072456A1"},{"key":"3978_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1039\/d3ob02091f","volume":"22","author":"VS Agostino","year":"2024","unstructured":"Agostino VS, Buerdsell ML, Uliana SRB et al (2024) Clemastine\/tamoxifen hybrids as easily accessible antileishmanial drug leads. Org Biomol Chem 22:1812\u20131820. https:\/\/doi.org\/10.1039\/d3ob02091f","journal-title":"Org Biomol Chem"},{"key":"3978_CR4","doi-asserted-by":"publisher","unstructured":"Akerlund A, Andersson M, Leflein J et al (2005) Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 115. https:\/\/doi.org\/10.1016\/j.jaci.2004.12.016","DOI":"10.1016\/j.jaci.2004.12.016"},{"key":"3978_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12035-014-9019-8","volume":"53","author":"S Apolloni","year":"2016","unstructured":"Apolloni S, Fabbrizio P, Parisi C et al (2016) Clemastine confers neuroprotection and induces an anti-inflammatory phenotype in SOD1G93A mouse model of amyotrophic lateral sclerosis. Mol Neurobiol 53:518\u2013531. https:\/\/doi.org\/10.1007\/s12035-014-9019-8","journal-title":"Mol Neurobiol"},{"key":"3978_CR6","doi-asserted-by":"publisher","unstructured":"Ayyad RR, Mansour AM, Nejm AM et al (2024) Stereo selectivity of histaminic receptors play an important role of anti-histaminic activity. Curr Res Med Sci 3:10\u201317. https:\/\/doi.org\/10.56397\/crms.2024.03.02","DOI":"10.56397\/crms.2024.03.02"},{"key":"3978_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/bmc.621","volume":"20","author":"E Brzezi\u0144ska","year":"2006","unstructured":"Brzezi\u0144ska E, Ko\u015bka G (2006) A structure-activity relationship study of compounds with antihistamine activity. Biomed Chromatogr 20:1004\u20131016. https:\/\/doi.org\/10.1002\/bmc.621","journal-title":"Biomed Chromatogr"},{"key":"3978_CR8","doi-asserted-by":"publisher","unstructured":"Carlstr\u00f6m KE, Zhu K, Ewing E et al (2020) Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis. Nat Commun 11. https:\/\/doi.org\/10.1038\/s41467-020-17871-5","DOI":"10.1038\/s41467-020-17871-5"},{"key":"3978_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1211\/0022357991772097","volume":"51","author":"MH Choi","year":"2010","unstructured":"Choi MH, Jung BH, Chung BC (2010) Identification of urinary metabolites of clemastine after oral administration to man. J Pharm Pharmacol 51:53\u201359. https:\/\/doi.org\/10.1211\/0022357991772097","journal-title":"J Pharm Pharmacol"},{"key":"3978_CR10","unstructured":"Cihlar T, Osinusi A, Porter DL (2020) Methods for treating SARS CoV-2 infections. AU 2024205205 Al. https:\/\/patents.google.com\/patent\/AU2024205205A1\/en?oq=AU2024205205A1"},{"key":"3978_CR11","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/brain\/awac207","volume":"145","author":"C Cordano","year":"2022","unstructured":"Cordano C, Sin JH, Timmons G et al (2022) Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy. Brain 145:3943\u20133952. https:\/\/doi.org\/10.1093\/brain\/awac207","journal-title":"Brain"},{"key":"3978_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/brain\/awx312","volume":"141","author":"BAC Cree","year":"2018","unstructured":"Cree BAC, Niu J, Hoi KK et al (2018) Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain 141:85\u201398. https:\/\/doi.org\/10.1093\/brain\/awx312","journal-title":"Brain"},{"key":"3978_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00415-019-09421-x","volume":"268","author":"N Cunniffe","year":"2021","unstructured":"Cunniffe N, Coles A (2021) Promoting remyelination in multiple sclerosis. J Neurol 268:30\u201344","journal-title":"J Neurol"},{"key":"3978_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11064-021-03465-0","volume":"47","author":"W Du","year":"2022","unstructured":"Du W, Deng Y, Jiang R et al (2022) Clemastine enhances myelination, delays axonal loss and promotes functional recovery in spinal cord injury. Neurochem Res 47:503\u2013515. https:\/\/doi.org\/10.1007\/s11064-021-03465-0","journal-title":"Neurochem Res"},{"key":"3978_CR15","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Berm\u00fadez MY, Freude KK, Mouhammad ZA et al (2021) Glial cells in glaucoma: Friends, foes, and potential therapeutic targets. Front Neurol 12. https:\/\/doi.org\/10.3389\/fneur.2021.624983","DOI":"10.3389\/fneur.2021.624983"},{"key":"3978_CR16","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA et al (2017) Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390:2481\u20132489. https:\/\/doi.org\/10.1016\/S0140-6736(17)32346-2","journal-title":"Lancet"},{"key":"3978_CR17","unstructured":"Hatchwell E, Eis PS, Smith EB, Aoufik Y (2023) Methods for assessing risk of developing a viral disease using a genetic test. Ep 4 177 356 A1. https:\/\/patents.google.com\/patent\/EP4177356A1\/en?oq=+++EP4177356A1"},{"key":"3978_CR18","unstructured":"Hoertel N,\u00a0Limosin F,\u00a0Sanchez Rico ML (2022). Use of hydroxyzine and antihistamine analogs for treating the covid-19 disease. EP3973961A1. https:\/\/patentimages.storage.googleapis.com\/ee\/1c\/5f\/719a82cdc3351f\/EP3973961A1.pdf"},{"key":"3978_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jchromb.2004.11.025","volume":"816","author":"V Horv\u00e1th","year":"2005","unstructured":"Horv\u00e1th V, Tolok\u00e1n A, Egresi A et al (2005) High-performance liquid chromatographic-tandem mass spectrometric method for the determination of clemastine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 816:153\u2013159. https:\/\/doi.org\/10.1016\/j.jchromb.2004.11.025","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3978_CR20","doi-asserted-by":"publisher","unstructured":"Imeri F, Stepanovska Tanturovska B, Zivkovic A et al (2021) Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis. Neuropharmacology 186. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108464","DOI":"10.1016\/j.neuropharm.2021.108464"},{"key":"3978_CR21","doi-asserted-by":"publisher","unstructured":"Jiang S, Wang X, Cao T et al (2023) Insights on therapeutic potential of clemastine in neurological disorders. Front Mol Neurosci 16. https:\/\/doi.org\/10.3389\/fnmol.2023.1279985","DOI":"10.3389\/fnmol.2023.1279985"},{"key":"3978_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5597","author":"LM Johansen","year":"2015","unstructured":"Johansen LM, Dewald LE, Shoemaker CJ et al (2015) A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa5597","journal-title":"Sci Transl Med"},{"key":"3978_CR23","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2011.06.023","volume":"128","author":"P Johansen","year":"2011","unstructured":"Johansen P, Weiss A, B\u00fcnter A et al (2011) Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines. J Allergy Clin Immunol 128:1286\u20131294. https:\/\/doi.org\/10.1016\/j.jaci.2011.06.023","journal-title":"J Allergy Clin Immunol"},{"key":"3978_CR24","unstructured":"Johnston L (2018) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant. CA3055936A1. https:\/\/patents.google.com\/patent\/CA3055936A1\/fi"},{"key":"3978_CR25","doi-asserted-by":"publisher","DOI":"10.1185\/03007998509109610","author":"DS Jolliffe","year":"1985","unstructured":"Jolliffe DS, Mrcp M, Sim-Davis D, Templeton S (1985) A placebo-controlled comparative study of sustained-release brompheniramine maleate against clemastine fumarate in the and treatment of chronic urticarial. Curr Med Res Opin. https:\/\/doi.org\/10.1185\/03007998509109610","journal-title":"Curr Med Res Opin"},{"key":"3978_CR26","unstructured":"Kivell BM, La Flamme AC, Prisinzano TE (2020). Treatment of demyelinating diseases. US 2021\/0023074 A1. https:\/\/patents.google.com\/patent\/US20210023074A1\/en?oq=US20210023074A1"},{"key":"3978_CR27","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s12272-015-0641-4","volume":"38","author":"SY Lee","year":"2015","unstructured":"Lee SY, Jung JW, Kim TH, Kim HD (2015) Asymmetric synthesis of H1 receptor antagonist (R, R)-clemastine. Arch Pharm Res 38:2131\u20132136. https:\/\/doi.org\/10.1007\/s12272-015-0641-4","journal-title":"Arch Pharm Res"},{"key":"3978_CR28","doi-asserted-by":"publisher","unstructured":"Lee J Il, Park JW, Lee KJ, Lee DH (2021) Clemastine improves electrophysiologic and histomorphometric changes through promoting myelin repair in a murine model of compression neuropathy. Sci Rep 11. https:\/\/doi.org\/10.1038\/s41598-021-00389-1","DOI":"10.1038\/s41598-021-00389-1"},{"key":"3978_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12264-015-1555-3","volume":"31","author":"Z Li","year":"2015","unstructured":"Li Z, He Y, Fan S, Sun B (2015) Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination. Neurosci Bull 31:617\u2013625. https:\/\/doi.org\/10.1007\/s12264-015-1555-3","journal-title":"Neurosci Bull"},{"key":"3978_CR30","doi-asserted-by":"publisher","unstructured":"Li ZY, Chen LH, Zhao XY et al (2021) Clemastine attenuates AD-like pathology in an AD model mouse via enhancing mTOR-mediated autophagy. Exp Neurol 342. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113742","DOI":"10.1016\/j.expneurol.2021.113742"},{"key":"3978_CR31","doi-asserted-by":"publisher","unstructured":"Matsumoto N, Ebihara M, Oishi S, et al (2021) Histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells. Sci Rep 11. https:\/\/doi.org\/10.1038\/s41598-021-81077-y","DOI":"10.1038\/s41598-021-81077-y"},{"key":"3978_CR32","doi-asserted-by":"publisher","unstructured":"Mei F, Lehmann-Horn K, Shen Y-AA et al (2016) Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. https:\/\/doi.org\/10.7554\/eLife.18246.001","DOI":"10.7554\/eLife.18246.001"},{"key":"3978_CR33","doi-asserted-by":"publisher","unstructured":"Meng S, Sun X, Juan Z et al (2021) Clemastine fumarate attenuates myocardial ischemia reperfusion injury through inhibition of mast cell degranulation. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.704852","DOI":"10.3389\/fphar.2021.704852"},{"key":"3978_CR34","doi-asserted-by":"publisher","unstructured":"Mike JK, White Y, Hutchings RS et al (2023) Effect of clemastine on neurophysiological outcomes in an ovine model of neonatal hypoxic-ischemic encephalopathy. Children 10. https:\/\/doi.org\/10.3390\/children10111728","DOI":"10.3390\/children10111728"},{"key":"3978_CR35","doi-asserted-by":"publisher","unstructured":"Moghaddasi M, Nabovvati M, koushki A et al (2020) Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis. Clin Neurol Neurosurg 193. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105741","DOI":"10.1016\/j.clineuro.2020.105741"},{"key":"3978_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4103\/1673-5374.355749","volume":"18","author":"A Myatich","year":"2023","unstructured":"Myatich A, Haque A, Sole C, Banik NL (2023) Clemastine in remyelination and protection of neurons and skeletal muscle after spinal cord injury. Neural Regen Res 18:940\u2013946","journal-title":"Neural Regen Res"},{"key":"3978_CR37","unstructured":"Nastaran M, Susan G, Maryam K et al (2022) Comparison of the effect of clemestine and placebo after intravenous corticosteroids in the treatment of acute optic neuritis. J Emerg Health Care. DOR: 20.1001.1.23222913.2022.11.1.1.2"},{"key":"3978_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03326-w","author":"EP Odell","year":"2024","unstructured":"Odell EP, Jabassini N, Schniedewind B et al (2024) Minimum effective dose of clemastine in a mouse model of preterm white matter injury. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-024-03326-w","journal-title":"Pediatr Res"},{"key":"3978_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41593-019-0582-1","volume":"23","author":"S Pan","year":"2020","unstructured":"Pan S, Mayoral SR, Choi HS et al (2020) Preservation of a remote fear memory requires new myelin formation. Nat Neurosci 23:487\u2013499. https:\/\/doi.org\/10.1038\/s41593-019-0582-1","journal-title":"Nat Neurosci"},{"key":"3978_CR40","doi-asserted-by":"publisher","unstructured":"Poon MM, Lorrain KI, Stebbins KJ et al (2024) Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis. Proc Natl Acad Sci U S A 121. https:\/\/doi.org\/10.1073\/pnas.2407974121","DOI":"10.1073\/pnas.2407974121"},{"key":"3978_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yjmcc.2005.09.017","volume":"40","author":"JM Ridley","year":"2006","unstructured":"Ridley JM, Milnes JT, Hancox JC, Witchel HJ (2006) Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. J Mol Cell Cardiol 40:107\u2013118. https:\/\/doi.org\/10.1016\/j.yjmcc.2005.09.017","journal-title":"J Mol Cell Cardiol"},{"key":"3978_CR42","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1523\/JNEUROSCI.1862-17.2018","volume":"38","author":"R Ross Welliver","year":"2018","unstructured":"Ross Welliver R, Polanco JJ, Seidman RA et al (2018) Muscarinic receptor M 3 R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci 38:6921\u20136932. https:\/\/doi.org\/10.1523\/JNEUROSCI.1862-17.2018","journal-title":"J Neurosci"},{"key":"3978_CR43","unstructured":"Ruxiang X,\u00a0Quanhong M,\u00a0Zhenyu L (2017) Use of clemastine or a composition thereof in the preparation of a medicament for treating Alzheimer\u2019s disease.\u00a0CN109512817A. https:\/\/patents.google.com\/patent\/CN109512817A\/en?oq=CN109512817A"},{"key":"3978_CR44","doi-asserted-by":"publisher","unstructured":"Schran HF, Petryk L, Chang CT et al (1996) The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol 36:911\u2013922. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04758.x","DOI":"10.1002\/j.1552-4604.1996.tb04758.x"},{"key":"3978_CR45","unstructured":"Schultz P, Lairson L, Deshmukh V, Lyssiotis C (2020). Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate. US20200390780A1. https:\/\/patents.google.com\/patent\/US20200390780A1\/en?oq=US20200390780A1"},{"key":"3978_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature10236","volume":"475","author":"T Shimamura","year":"2011","unstructured":"Shimamura T, Shiroishi M, Weyand S et al (2011) Structure of the human histamine H 1 receptor complex with doxepin. Nature 475:65\u201372. https:\/\/doi.org\/10.1038\/nature10236","journal-title":"Nature"},{"key":"3978_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-9733.2011.01159.x","author":"N Shimojo","year":"2012","unstructured":"Shimojo N (2012) Safety of antihistamines in children: need for approval of new second-generation antihistamines for young children in Japan. Clinical & Experimental Allergy Reviews. https:\/\/doi.org\/10.1111\/j.1472-9733.2011.01159.x","journal-title":"Clinical & Experimental Allergy Reviews"},{"key":"3978_CR48","doi-asserted-by":"publisher","unstructured":"Simons FER, Simons KJ (2011) Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunoly 128. https:\/\/doi.org\/10.1016\/j.jaci.2011.09.005","DOI":"10.1016\/j.jaci.2011.09.005"},{"key":"3978_CR49","doi-asserted-by":"publisher","unstructured":"Su WJ, Zhang T, Jiang CL, Wang W (2018) Clemastine alleviates depressive-like behavior through reversing the imbalance of microglia-related pro-inflammatory state in mouse hippocampus. Front Cell Neurosci 12. https:\/\/doi.org\/10.3389\/fncel.2018.00412","DOI":"10.3389\/fncel.2018.00412"},{"key":"3978_CR50","doi-asserted-by":"publisher","unstructured":"Sun MA, Yang R, Liu H et al (2023) Repurposing clemastine to target glioblastoma cell stemness. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15184619","DOI":"10.3390\/cancers15184619"},{"key":"3978_CR51","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/rcm.1622","volume":"18","author":"A Tevell","year":"2004","unstructured":"Tevell A, Bondesson U, T\u00f6rneke K, Hedeland M (2004) Identification of some new clemastine metabolites in dog, horse, and human urine with liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrom 18:2267\u20132272. https:\/\/doi.org\/10.1002\/rcm.1622","journal-title":"Rapid Commun Mass Spectrom"},{"key":"3978_CR52","doi-asserted-by":"publisher","unstructured":"Tong LY, Deng YB, Du WH et al (2022) Clemastine promotes differentiation of oligodendrocyte progenitor cells through the activation of ERK1\/2 via muscarinic receptors after spinal cord injury. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.914153","DOI":"10.3389\/fphar.2022.914153"},{"key":"3978_CR53","doi-asserted-by":"publisher","first-page":"7134","DOI":"10.1080\/21655979.2022.2047256","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Xie D, Dai H et al (2022) Clemastine protects against sepsis-induced myocardial injury in vivo and in vitro. Bioengineered 13:7134\u20137146. https:\/\/doi.org\/10.1080\/21655979.2022.2047256","journal-title":"Bioengineered"},{"key":"3978_CR54","doi-asserted-by":"publisher","unstructured":"Wu W, Zhang X, Zhou J et al (2021a) Clemastine ameliorates perioperative neurocognitive disorder in aged mice caused by anesthesia and surgery. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.738590","DOI":"10.3389\/fphar.2021.738590"},{"key":"3978_CR55","doi-asserted-by":"publisher","unstructured":"Wu W, Zhang X, Zhou J, et al (2021b) Clemastine ameliorates perioperative neurocognitive disorder in aged mice caused by anesthesia and surgery. Front Pharmacol 12:. https:\/\/doi.org\/10.3389\/fphar.2021.738590","DOI":"10.3389\/fphar.2021.738590"},{"key":"3978_CR56","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jpba.2007.03.019","volume":"44","author":"Z Xie","year":"2007","unstructured":"Xie Z, Liao Q, Li Z et al (2007) Development and full validation of a sensitive quantitative assay for the determination of clemastine in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 44:924\u2013930. https:\/\/doi.org\/10.1016\/j.jpba.2007.03.019","journal-title":"J Pharm Biomed Anal"},{"key":"3978_CR57","doi-asserted-by":"publisher","unstructured":"Xie D, Ge X, Ma Y et al (2020) Clemastine improves hypomyelination in rats with hypoxic-ischemic brain injury by reducing microglia-derived IL-1\u03b2 via P38 signaling pathway. J Neuroinflammation 17. https:\/\/doi.org\/10.1186\/s12974-019-1662-6","DOI":"10.1186\/s12974-019-1662-6"},{"key":"3978_CR58","doi-asserted-by":"publisher","unstructured":"Xie YY, Pan TT, Xu DE et al (2021) Clemastine ameliorates myelin deficits via preventing senescence of oligodendrocytes precursor cells in Alzheimer\u2019s disease model mouse. Front Cell Dev Biol 9. https:\/\/doi.org\/10.3389\/fcell.2021.733945","DOI":"10.3389\/fcell.2021.733945"},{"key":"3978_CR59","doi-asserted-by":"publisher","unstructured":"Yuan X, Juan Z, Zhang R et al (2020) Clemastine fumarate protects against myocardial ischemia reperfusion injury by activating the TLR4\/PI3K\/Akt Signaling Pathway. Front Pharmacol 11. https:\/\/doi.org\/10.3389\/fphar.2020.00028","DOI":"10.3389\/fphar.2020.00028"},{"key":"3978_CR60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.7150\/ijms.51150","volume":"18","author":"C Zhi","year":"2021","unstructured":"Zhi C, Zeng S, Chen Y et al (2021) Clemastine promotes recovery of neural function and suppresses neuronal apoptosis by restoring balance of pro-inflammatory mediators in an experimental model of intracerebral hemorrhage. Int J Med Sci 18:639\u2013645. https:\/\/doi.org\/10.7150\/ijms.51150","journal-title":"Int J Med Sci"},{"key":"3978_CR61","doi-asserted-by":"publisher","unstructured":"Zhu T Ting, Wang H, Liu P Miao et al (2024) Clemastine-induced enhancement of hippocampal myelination alleviates memory impairment in mice with chronic pain. Neurobiol Dis 190. https:\/\/doi.org\/10.1016\/j.nbd.2023.106375","DOI":"10.1016\/j.nbd.2023.106375"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03978-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:39:34Z","timestamp":1757151574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3978"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03978-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}